MeiraGTx has handed off the remaining interests for a rare disease gene therapy to Johnson & Johnson in a deal that could reach $415 million. The agreement involves botaretigene sparoparvovec, or bota-vec, formerly AAV-RPGR, which is in development for X-linked retinitis pigmentosa. The therapy was developed through a partnership with J&J’s Janssen unit, but now the healthcare giant wants the whole program. Source: Fierce Biotech 21/12/2023